Թϴͷ

Թϴͷ Sets Up a Subsidiary in Austria

Թϴͷ Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Թϴͷ”) announced today that the Company had established its new subsidiary, Թϴͷ GesmbH (Location: Vienna, General Manager: Georg Wager, “Թϴͷ Austria”) in Austria. Թϴͷ Austria is a subsidiary wholly-owned by Թϴͷ Europe Limited (Headquarters: Hatfield, UK, Chairman & CEO: Yutaka Tsuchiya, “Թϴͷ Europe”), the European subsidiary of Թϴͷ.

Թϴͷ entered into the Austrian market in 2005 setting up a branch of its German subsidiary Թϴͷ GmbH (Location: Frankfurt, Managing Director: Andreas Wiegand). The Austrian branch has been marketing Zonegran® and Inovelon® for the treatment of epilepsy, Neurobloc® for cervical dystonia, Prialt® for severe chronic pain, and also collaborating in the promotion of Aricept® for Alzheimer's Disease. It has also served as a support centre for marketing, medical and regulatory affairs for the business operations in Central and Eastern Europe.

With the establishment of a subsidiary in Austria, a subsidiary wholly-owned by Թϴͷ Europe, Թϴͷ will strengthen its business operations in Austria and Central and Eastern European countries in preparation for future possible business expansion in this region.

Թϴͷ currently has ten subsidiaries in Europe with the newly established Թϴͷ Austria. Թϴͷ will continue to strengthen its business operations in Europe and to address the diversified needs of patients and their families, thereby improving patient value.

[Թϴͷ Austria's Outline]

*You can scroll to the left or right here

Company Name : Թϴͷ GesmbH
Date of Establishment : April 1, 2009
Capital : 35 thousand euros
Location : Vienna, Austria
General Manager : Georg Wager
Business Operations : Sales and Promotion of Pharmaceutical Products

Contact:

PR Department
Թϴͷ Co., Ltd.

+81-(0)3-3817-5120